{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:01Z","timestamp":1790790181579,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ejim.2020.09.025","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T09:45:20Z","timestamp":1601891120000},"page":"7-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3307-0825","authenticated-orcid":false,"given":"Aldostefano","family":"Porcari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Rapezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2020.09.025_bib0001","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.09.025_bib0002","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","volume":"40","author":"Emdin","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.09.025_bib0003","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2019.12.033","article-title":"The Alzheimer's Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease","volume":"75","author":"Stakos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.09.025_bib0004","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","author":"Rapezzi","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2020.09.025_bib0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ejim.2013.10.007","article-title":"Systemic amyloidoses: what an internist should know","volume":"24","author":"Palladini","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.09.025_bib0006","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.09.025_bib0007","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejim.2018.05.029","article-title":"Monoclonal gammopathies of unknown significance and smoldering myeloma: assessment and management of the elderly patients","volume":"58","author":"Gonz\u00e1lez-Calle","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.09.025_bib0008","first-page":"12","article-title":"Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis","author":"Maurer","year":"2019","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.ejim.2020.09.025_bib0009","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.09.025_bib0010","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","article-title":"Aortic Stenosis and Cardiac Amyloidosis","volume":"74","author":"Ternacle","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.09.025_bib0011","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.09.025_bib0012","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.09.025_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.09.025_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2019.07.022","article-title":"Cardiac amyloidosis: an underdiagnosed\/underappreciated disease","volume":"67","author":"Manolis","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.09.025_bib0015","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","author":"Damy","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.09.025_bib0016","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.09.025_bib0017","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Hear Fail"},{"key":"10.1016\/j.ejim.2020.09.025_bib0018","doi-asserted-by":"crossref","unstructured":"Vergaro G., Aimo A., Barison A., Genovesi D., Buda G., Passino C., et\u00a0al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. Eur J Prev Cardiol 2019:204748731987770. 10.1177\/2047487319877708.","DOI":"10.1177\/2047487319877708"},{"key":"10.1016\/j.ejim.2020.09.025_bib0019","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ejhf.1742","article-title":"Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies","volume":"22","author":"Milandri","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2020.09.025_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ejim.2020.09.025_bib0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacc.2019.04.054","article-title":"Association of Carpal Tunnel Syndrome With Amyloidosis, Heart Failure, and Adverse Cardiovascular Outcomes","volume":"74","author":"Fosb\u00f8l","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.09.025_bib0022","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jchf.2020.03.007","article-title":"Utility of Biomarkers in Cardiac Amyloidosis","volume":"8","author":"Pregenzer-Wenzler","year":"2020","journal-title":"JACC Hear Fail"},{"key":"10.1016\/j.ejim.2020.09.025_bib0023","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11897-020-00457-z","article-title":"Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis","volume":"17","author":"Hendren","year":"2020","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.ejim.2020.09.025_bib0024","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamacardio.2016.5864","article-title":"Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model","volume":"2","author":"Arvanitis","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2020.09.025_bib0025","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.1093\/eurheartj\/suaa080","article-title":"Cardiac amyloidosis: do not forget to look for it","volume":"22","author":"Porcari","year":"2020","journal-title":"Eur Hear J Suppl"},{"key":"10.1016\/j.ejim.2020.09.025_bib0026","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2020.09.025_bib0027","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.09.025_bib0028","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2020.09.025_bib0029","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.09.025_bib0030","article-title":"Management of complications of cardiac amyloidosis: 10 questions and answers","author":"Aimo","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ejim.2020.09.025_bib0031","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1440-1827.1995.tb03466.x","article-title":"Incidence and distribution of isolated atrial amyloid: histologic and immunohistochemical studies of 100 aging hearts","volume":"45","author":"Kawamura","year":"1995","journal-title":"Pathol Int"},{"key":"10.1016\/j.ejim.2020.09.025_bib0032","first-page":"193","article-title":"Pathological study on amyloidosis -relationship of amyloid deposits in the aorta to aging","volume":"28","author":"Iwata","year":"1978","journal-title":"Pathol Int"},{"key":"10.1016\/j.ejim.2020.09.025_bib0033","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","article-title":"Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation","volume":"41","author":"Scully","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.09.025_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2020.05.015","article-title":"Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis","author":"Aimo","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.09.025_bib0035","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.09.025_bib0036","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen A","year":"2008","journal-title":"Hear Rhythm"},{"key":"10.1016\/j.ejim.2020.09.025_bib0037","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ejim.2020.09.025_bib0038","article-title":"Unveiling Outcomes in Coexisting Severe Aortic Stenosis and Transthyretin Cardiac Amyloidosis","author":"Rosenblum","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2020.09.025_bib0039","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations*","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2020.09.025_bib0040","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1073\/pnas.202495199","article-title":"Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity","volume":"99","author":"Hammarstrom","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ejim.2020.09.025_bib0041","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin Amyloid Cardiomyopathy","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.09.025_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2020.02.030","article-title":"Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis","author":"Grigoratos","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2020.09.025_bib0043","article-title":"[18F]-Florbetaben PET\/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions","author":"Genovesi","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2020.09.025_bib0044","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.09.025_bib0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Gonzalez-Duarte A, O'Riordan WD, Yang C-C, Ueda M, Kristen A V., et\u00a0al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2020.09.025_bib0046","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2020.09.025_bib0047","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/eurheartj\/ehz695","article-title":"A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model","volume":"41","author":"George","year":"2020","journal-title":"Eur Heart J"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520303770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520303770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:32:13Z","timestamp":1760607133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620520303770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":47,"alternative-id":["S0953620520303770"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2020.09.025","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2020.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}